Cantor Fitzgerald Weighs in on Korro Bio FY2025 Earnings

Korro Bio, Inc. (NASDAQ:KRRO) – Equities researchers at Cantor Fitzgerald upped their FY2025 earnings per share (EPS) estimates for shares of Korro Bio in a report released on Thursday, May 8th. Cantor Fitzgerald analyst S. Seedhouse now expects that the company will earn ($8.76) per share for the year, up from their prior estimate of ($8.91). Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($9.52) per share.

Korro Bio (NASDAQ:KRRO) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($2.49) earnings per share for the quarter, beating the consensus estimate of ($2.60) by $0.11. The company had revenue of $2.55 million during the quarter, compared to analyst estimates of $0.13 million.

KRRO has been the topic of several other research reports. HC Wainwright dropped their price target on Korro Bio from $115.00 to $100.00 and set a “buy” rating on the stock in a research note on Thursday, May 8th. Oppenheimer dropped their target price on Korro Bio from $155.00 to $90.00 and set an “outperform” rating on the stock in a research report on Tuesday. Chardan Capital reaffirmed a “buy” rating and set a $25.00 price target on shares of Korro Bio in a research report on Tuesday. Finally, Royal Bank of Canada decreased their price target on shares of Korro Bio from $105.00 to $95.00 and set an “outperform” rating for the company in a research note on Wednesday, March 19th. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $104.63.

Korro Bio Trading Down 2.7%

KRRO opened at $15.55 on Monday. The stock has a market capitalization of $146.03 million, a P/E ratio of -1.65 and a beta of 2.66. Korro Bio has a 12 month low of $11.13 and a 12 month high of $98.00. The firm’s fifty day simple moving average is $17.53 and its 200 day simple moving average is $33.59.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. KLP Kapitalforvaltning AS acquired a new stake in shares of Korro Bio in the 4th quarter valued at approximately $53,000. AlphaQuest LLC raised its position in Korro Bio by 23.2% during the fourth quarter. AlphaQuest LLC now owns 2,189 shares of the company’s stock worth $83,000 after acquiring an additional 412 shares in the last quarter. Wells Fargo & Company MN lifted its stake in Korro Bio by 32.4% in the fourth quarter. Wells Fargo & Company MN now owns 3,392 shares of the company’s stock valued at $129,000 after acquiring an additional 831 shares during the last quarter. Deutsche Bank AG grew its position in shares of Korro Bio by 29.4% in the 4th quarter. Deutsche Bank AG now owns 4,110 shares of the company’s stock valued at $156,000 after acquiring an additional 935 shares during the period. Finally, Legal & General Group Plc grew its position in shares of Korro Bio by 664.1% in the 4th quarter. Legal & General Group Plc now owns 4,325 shares of the company’s stock valued at $165,000 after acquiring an additional 3,759 shares during the period. 13.18% of the stock is currently owned by institutional investors.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).